Detalhe da pesquisa
1.
Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [111In]In-Radioligands: Synthesis and Preclinical Profile.
Int J Mol Sci
; 25(3)2024 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38339198
2.
[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial.
Eur J Nucl Med Mol Imaging
; 50(3): 892-907, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36334104
3.
Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity.
Eur J Nucl Med Mol Imaging
; 49(13): 4440-4451, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35951084
4.
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Eur J Nucl Med Mol Imaging
; 49(11): 3627-3638, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35556158
5.
Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
Int J Mol Sci
; 23(14)2022 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35887398
6.
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Eur J Nucl Med Mol Imaging
; 48(5): 1339-1350, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33094433
7.
Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma.
J Neurooncol
; 153(2): 211-222, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33768405
8.
Imaging inflammation in atherosclerotic plaques, targeting SST2 with [111In]In-DOTA-JR11.
J Nucl Cardiol
; 28(6): 2506-2513, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32026330
9.
Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach.
Eur J Nucl Med Mol Imaging
; 47(12): 2856-2865, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32291511
10.
[99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models.
Molecules
; 25(15)2020 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731473
11.
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
Int J Cancer
; 145(12): 3347-3358, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31077356
12.
Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability.
J Labelled Comp Radiopharm
; 62(10): 646-655, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30963606
13.
Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair.
Molecules
; 24(6)2019 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30871262
14.
Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
Bioconjug Chem
; 29(5): 1774-1784, 2018 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29664606
15.
Translational molecular imaging in exocrine pancreatic cancer.
Eur J Nucl Med Mol Imaging
; 45(13): 2442-2455, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30225616
16.
Correction to: In vitro dose effect relationships of actinium225 and lutetium177labeled PSMAI&T.
Eur J Nucl Med Mol Imaging
; 49(11): 3956-3957, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35614268
17.
Preclinical in vivo cancer, straightway to patients?
Q J Nucl Med Mol Imaging
; 61(2): 145-152, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28347131
18.
Intravenous and intratumoral injection of Pluronic P94: The effect of administration route on biodistribution and tumor retention.
Nanomedicine
; 13(7): 2179-2188, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28535990
19.
Review: Receptor Targeted Nuclear Imaging of Breast Cancer.
Int J Mol Sci
; 18(2)2017 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28134770
20.
NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice.
Molecules
; 22(11)2017 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29137110